Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $58.67.
A number of research firms have weighed in on XENE. Robert W. Baird began coverage on shares of Xenon Pharmaceuticals in a research report on Friday, December 8th. They set an “outperform” rating and a $63.00 price objective on the stock. Needham & Company LLC increased their price objective on shares of Xenon Pharmaceuticals from $50.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $54.00 to $59.00 and gave the company an “outperform” rating in a research report on Tuesday, December 19th. Bank of America increased their price target on Xenon Pharmaceuticals from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Wedbush boosted their price objective on Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a report on Friday, March 1st.
Check Out Our Latest Research Report on XENE
Insider Activity
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Walleye Capital LLC boosted its position in Xenon Pharmaceuticals by 40.5% during the third quarter. Walleye Capital LLC now owns 126,028 shares of the biopharmaceutical company’s stock valued at $4,305,000 after purchasing an additional 36,324 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Xenon Pharmaceuticals by 64.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,728,108 shares of the biopharmaceutical company’s stock valued at $59,032,000 after buying an additional 677,057 shares in the last quarter. TimesSquare Capital Management LLC grew its position in shares of Xenon Pharmaceuticals by 38.3% in the 3rd quarter. TimesSquare Capital Management LLC now owns 590,575 shares of the biopharmaceutical company’s stock worth $20,174,000 after buying an additional 163,650 shares during the last quarter. Barclays PLC grew its position in shares of Xenon Pharmaceuticals by 3.7% in the 3rd quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 342 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in shares of Xenon Pharmaceuticals by 22.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 3,967 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 720 shares in the last quarter. 95.45% of the stock is owned by institutional investors.
Xenon Pharmaceuticals Trading Up 0.1 %
XENE opened at $43.05 on Friday. The stock has a 50-day moving average of $46.17 and a 200 day moving average of $40.18. Xenon Pharmaceuticals has a 12 month low of $27.99 and a 12 month high of $50.99. The firm has a market cap of $3.25 billion, a P/E ratio of -15.83 and a beta of 1.17.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.12. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.57) earnings per share. On average, research analysts forecast that Xenon Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- Short Selling: How to Short a Stock
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is a Dividend King?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.